ArticleApplied biochemistry and biotechnology2025
In-vitro Analysis of Solanum virginianum L. Extract and Melatonin: Synergistic Induction of Apoptosis in MDA-MB-231 Breast Cancer Cells.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phyto-capped CuO Nanoparticles with Enhanced Antimicrobial and Anticancer Efficacy Against MCF-7 Cell Line: A Green Nanotherapeutic Approach.Applied biochemistry and biotechnology · 2026Article
- Mechanistic Insights into metformin's neuroprotective effects against drug-induced neurotoxicity.Metabolic brain disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solanum virginianum (Sv) herb finds widespread usage in various medical systems, notably it is a component of the traditional herbal formulation "Dashamula". Melatonin is widely acknowledged as a chemical and a cell defender owing to its anti-oxidative and immunomodulatory properties. Despite extensive references in traditional medicine, systematic evaluations of Solanum virginianum anticancer properties are scarce. Combination therapy has emerged as a promising strategy for tackling drug-resistant cancers, inhibiting tumour progression, and enhancing therapeutic efficacy. This study aims to investigate the anticancer effects of Solanum virginianum plant extract and melatonin, individually and in combination, on breast cancer cells. The anticancer potential of individual treatments, as well as combinations of Solanum virginianum leaf extract and melatonin, was evaluated using cell migration inhibition, clonogenic assay, DNA fragmentation assay, nuclear morphology study, flow cytometry (FACS) analysis, and gene expression investigation. The methanolic leaf extracts of Solanum virginianum demonstrated significant anti-proliferative effects on MDA-MB-231 breast cancer cells. Furthermore, the combination of Solanum virginianum methanolic leaf extract and melatonin exhibited anti-migratory and anti-tumorigenic properties. This was further confirmed by gene expression studies related to both intrinsic and extrinsic apoptotic pathways. Notably, In combination groups, there was an increased expression of apoptotic genes (CASP3 (p < 0.001), CASP8 (p < 0.05), CASP9 (p < 0.05), BAX (p < 0.01) and anti-inflammatory genes (IL4, IL10), along with a decreased expression of the anti-apoptotic gene (BCL2) and metastatic genes (MMP2, MMP9). Overall, present study is the first comprehensive investigation into the potential of Solanum virginianum as an anticancer agent in conjunction with melatonin, highlighting the promising application of a combination approach for breast cancer treatment.
Indexed as
Identifiers
40637800What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.